Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available.
R. E. Martell
No relevant relationships to disclose
E. G. Chiorean
No relevant relationships to disclose
H. Youssoufian
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
M. D. Rutstein
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
B. Pytowski
Employment or Leadership Position - ImClone Systems
L. Benjamin
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
L. Abad
Employment or Leadership Position - ImClone Systems
J. Patel
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
T. Steele
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
M. Dowd
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
A. Qin
Employment or Leadership Position - ImClone Systems
C. F. Kukel
Employment or Leadership Position - ImClone Systems
F. E. Fox
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
A. Dontabhaktuni
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
A. Morozov
Employment or Leadership Position - ImClone Systems